We describe our 9-year experience with lectin-treated, Tcell-depleted haplocompatible parental bone marrow transplantation (BMT) for 24 patients with severe combined immunodeficiency disease (SCID). Nineteen of 21 evaluable patients had T-cell engraftment; 2 of 11 patients tested had B-cell and monocyte engraftment. Fourteen of 24 (58%) patients are alive 7 months to 9.8 years post-BMT. Seventeen of 24 patients received pretransplant conditioning with chemotherapy and/or total body irradiation, and 8 of 24 received more than one transplant. Patients who received conditioning had a survival rate of 61 % versus 57%
We describe our 9-year experience with lectin-treated, Tcell-depleted haplocompatible parental bone marrow transplantation (BMT) for 24 patients with severe combined immunodeficiency disease (SCID). Nineteen of 21 evaluable patients had T-cell engraftment; 2 of 11 patients tested had B-cell and monocyte engraftment. Fourteen of 24 (58%) patients are alive 7 months to 9.8 years post-BMT. Seventeen of 24 patients received pretransplant conditioning with chemotherapy and/or total body irradiation, and 8 of 24 received more than one transplant. Patients who received conditioning had a survival rate of 61 % versus 57%
for those who received no conditioning. None received graftversus-host disease (GVHD) prophylaxis and no patient had acute or chronic GVHD greater than grade I. Kinetics and follow-up of immune recovery were analyzed in 14 patients who are greater than 1 year from transplant. Half of the patients showed evidence of T-cell function by 3 months ONE MARROW transplantation (BMT) is the treatment B of choice for patients with severe combined immunodeficiency disease (SCID).' Because most patients lack an HLA-matched donor, various methods of T-cell depletion from donor marrow have been developed that enable transplantation of haplocompatible (parental) marrow with excellent rates of engraftment and minimal graft-versus-host disease (GVHD).2-7 However, immune reconstitution may be delayed and, especially in the case of B-cell function, sometimes incomplete.7-' '
We report our results in all 24 patients with SCID who were recipients of soybean agglutinin-treated, T-cell-depleted haplocompatible BMT. We describe in detail the kinetics and outcome of T-and B-cell reconstitution in 14 patients who have been observed for more than 12 months, and the chimeric status in 11 of those patients. We also attempt to identify the factors that influenced the outcome.
PATIENTS
Between July 1982 and October 199 I, 24 patients with SCID who lacked an HLA-matched donor received 36 haplocompatible T-celldepleted BMT. The clinical characteristics of these patients are shown in Table I . Our early experience in 8 of these patients was reported previ~usly.'~'~ Of the 24 patients, 14 were male, 3 of whom had family histories consistent with an X-linked inheritance. Two of these (unique patient number [UPN] 1 and 10) were initially treated with fetal thymus grafts in infancy. Engraftment occurred in both cases, although there was limited T-cell immune reconstitution. The latter patient developed chronic lung disease from repeated pneumonias and, at the time of BMT, had a virtual absent response to phytohemagglutinin (PHA) and was significantly lymphopenic (Table 2) . Ten patients had a known autosomal recessive inheritance, with 4 of these being Navajo Indians and 3 others having adenosine deaminase (ADA) deficiency.
As shown in Table 2 , only 1 patient had a normal pretransplant absolute lymphocyte count, 9 had normal or elevated B cells (absolute number and/or percentage of lymphocytes), and only 1 had a normal number of T cells. None of the patients had a detectable (>3 SD and normal T-cell function by 4 to 7 months post-BMT. On average, T-cell numbers and subsets became normal 10 to 12 months posttransplant. Recovery of B-cell function was more delayed, although in most patients B-cell numbers and IgM levels were normal by 12 months post-BMT. Bcell function, as determined by isohemagglutinin titers or specific antibodies to pneumococcal polysaccharide, keyhole limpet hemocyanin, or tetanus toxoid, became normal in 10 of 14 patients 2 to 8 years post-BMT. Seven of the 14 are off gammaglobulin therapy. Production of isohemagglutinins tended to predict recovery of antibody response to pneumococcal polysaccharide (P < .064). Based on these results, we believe that haplocompatible BMT is an effective, curative treatment for patients with SCID who lack an HLA-matched related donor.
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above resting) in vitro lymphocyte response to PHA and only 2 had a normal response to alloantigen (95% confidence limits).
Three patients (UPN 2, 3, and 9) had clinical evidence of GVHD within 3 months of birth consistent with maternal engraftment, although this could not be documented by HLA typing. A fourth patient (UPN 61) had maternal T cells documented in his peripheral blood by HLA typing.
All donors were parents (17 mothers and 19 fathers); 13 donor/ recipient pairs had 3 of 6 matched HLA loci (ie, HLA-A, B, Dr), 9 pairs had a 4 of 6 match, and 2 pairs had a 5 of 6 match. In 12 of 24, the mixed lymphocyte reaction (MLR) was reactive; in 4 of the remaining 12, it was nonreactive (all 4 were Dr matched with their donors); in 8, it was uninterpretable and unable to be repeated. The criteria for donor selection were (in order of preference): HLA-typing, cytomegalovirus (CMV) serology, and blood type. When there was no evidence for engraftment, generally after 3 months following the initial transplant, if possible, the other parent was used as a donor.
After BMT, patients were observed every month for the first 6 months, every 3 months for 2 years, and then every 6 months. Fourteen of the 24 patients were observed sequentially for more than 1 year post-BMT, and we describe the kinetics of their reconstitution and the most recent follow-up below.
All BMTs and subsequent studies were performed with the written informed consent of the patients' parents. 
METHODS
All ofthe marrows were processed by soybean agglutination (SBA) and 2 cycles of sheep erythrocyte rosetting, using a previously described technique.' The cell recovery was 5% to IO%, and the range of cell dose administered was 0.5 X 10' to 8.4 X lo8 nucleated marrow cells (NMC)/kg body weight (median, 1.7 X 10' NMC/kg). The final preparations contained less than 1% SBA positive and less than 1% CD3+ T cells (by fluorescent-conjugated monoclonal antibody [MoAb] staining) and had no detectable proliferative responses to PHA or alloantigen. Limiting dilution studies performed on recent procedures show less than 0.015% T-cell contamination in the final cell preparation (data not shown).
Engraftment was determined by HLA typing of peripheral blood mononuclear cells, using standard microlymphmytotoxicity techniques and, when appropriate, by in situ hybridization with probes to the X and Y chromosomes. In I 1 patients, HLA typing was performed separately on purified cell populations; T cells and non-T cells (B cells and monocytes) were separated by rosetting with neuraminidase-treated sheep erythrocytes, and monocytes were further purified by Percoll (Pharmacia, Piscataway, NJ) density gradient centrifugation.'' T and B lymphocytes and their subsets were enumerated by binding fluorescent-conjugated MoAbs to human cell surface antigens (CD3, CD4, CD8, leu& CD16, CD19, and CD16/56) and analyzing them on a FACScan (Becton Dickinson, Mountain View, CA). Leu8 binds to the homologue of the murine lymph node homing receptor and on the majority of normal human peripheral blood CD4+ T cells. CD4' leu% cells provide high helper
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Abbreviations: R, resting cell counts; S -R, stimulated minus resting cell counts; NA, not available; ND, not determined. Lower limit of normal (95% confidence) at 1 year of age activity to in vitro Ig production, whereas CD4+ leu8+ T cells inhibit production.14 Lymphocyte proliferation in response to PHA, pokeweed mitogen (PWM), candida dbicans antigen, and alloantigen (MLR) was measured by the incorporation of [3H]thymidine, as previously described. 15 Briefly, for PHA stimulation, 2,500 cells/well were cultured in roundbottom microculture plates for 7 days; for PWM stimulation, IO4 cells/well were cultured with varying dilutions of PWM (1: Lymphocyte response to tetanus toxoid antigen was measured after 1 to 3 immunizations. Briefly, lo5 cells/well were cultured in roundbottom microculture plates with tetanus toxoid (TT) 0.5 Lf/mL (Massachusetts State Dept. of Public Health Labs, Boston, MA); the cells were labeled with ['Hlthymidine on day 7 and harvested on day 8. Lymphocyte response to Stuphylococcus aureus (Cowan) (SAC; Calbiochem, La Jolla, CA) was determined by culturing 2 X IO5 cells/well in round-bottom microculture plates with SAC 5 X (wt/vol) for 48 hours, and [3H]thymidine pulsing during the last 4 hours.
In all proliferative assays, the mean resting counts (without mitogen, antigen, or alloantigen) were subtracted from the mean stimulated counts. Replicate (3 to 5) cultures were made at each culture condition. Normal controls were tested simultaneously with each patient's sample and normal values (95% confidence limits) were derived from greater than 100 control experiments for each assay.
Surface Igs were measured by binding a fluorescent MoAb to the Ig superfamily (CD19). Serum Ig concentrations were determined by nephelometry.
Patients were immunized with pneumococcal polysaccharide (PPS) and keyhole limpet hemocyanin (KLH) at 6-month intervals beginning at 6 months posttransplant; more recently, patients have also been immunized with TT. Initially, all patients were on intravenous (IV) or intramuscular (IM) gammaglobulin. The immunizations were administered 2 weeks after the dose of gammaglobulin and the postserum sample obtained just before the next dose. Antibodies to PPS, KLH, and TT were assayed initially by indirect hemagglutination16 and, more recently, by an enzyme-linked immunosorbent assay (ELISA).'7. '8 For statistical analyses, data were analyzed by using the Fisher exact probability
RESULTS

Clinical Engraftment
As shown i n Table 1 , 24 patients received a BMT. The patients did not receive GVHD prophylaxis and only three patients (UPN2, UPN9, and UPNlOS) had acute and/or chronic GVHD, all less than grade 11. I n 12 patients, the initial transplant was performed without pretransplant conditioning chemotherapy (or ATG or deoxyadenosine'* alone). Five of these patients engrafted after the first transplant and 4 patients engrafted after repeat B M T with cytoreductive therapy. O n e ofthese 4 patients ( U P N 5 1) had maternal cells from the original transplant appear after the conditioning and a paternal marrow transplant. T h e patient was subse- Abbreviation: NA, not available.
Thirty percent E-cell contamination.
t B cells and monocytes, unseparated.
* Seventeen percent T-cell contamination. quently boosted with a second maternal marrow. The remaining 3 patients were ADA deficient; one parent refused a second transplant, one again failed to engraft after conditioning with anti-Leu 1 (UPN 12), and the other patient died within 1 week of conditioning therapy and was unevaluable. Twelve patients received cytoreductive conditioning therapy before their initial BMT. Three of 4 patients who received conditioning before BMT; [O] no conditioning). ALC, absolute lymphocyte count (normal was adjusted for 95% confidence limit for age); ATC, absolute T-cell count; ACD4, absolute CD4+ cell count; ACD8, absolute CD8+ cell count; T4h. percentage of CD4 helper cells (5% to 26% of lymphocytes): T4i. CD4-inducer cells (1 7% to 39% of lymphocytes); PHA, proliferative response to PHA greater than 7,000 cpm; PWM, proliferative response to PWM greater than 1,500 cpm; MLR, :yclophosphamide (200 mg/kg) and ATG (80 mg/kg) engrafted. The remaining patient required two additional transplants: the second with cyclophosphamide, ATG, and total body irradiation (TBI) to achieve engraftment, followed by a boost with no conditioning to accelerate immune re-:onstitution. Seven patients received before their initial rransplant either cyclophosphamide ( 120 mg/kg), ATG (80 mg/kg), and 750 rads TBI with 50% shielding of the brain Ind lungs23 or busulfan (16 mg/kg), cyclophosphamide (200 mg/kg), and ATG (80 mg/kg). Five of these 7 patients engrafted; the remaining 2 patients died less than 2 weeks from BMT and were unevaluable. One of 13 patients was initially :onditioned with imuran, prednisone, and ATG (UPN3) and railed to engraft. This patient had two additional transplants, me with Cy/TBI and the other with Bu/Cy, and only after the third transplant did he engraft, but died in septic shock 2.5 months later.
Durable T-cell engraftment was achieved in 19 of 2 1 evaluable patients, with 6 of 19 requiring more than one transplant to achieve engraftment. Both of the evaluable patients who failed to engraft had ADA-deficient SCID. Looking at 111 3 1 evaluable transplants, pretransplant conditioning pos-.lively affected engraftment ( P = .025) whereas cell dose, pa-:ient's age, and donor and patient sex had no observable effect Jn engraftment rates ( P > .1).
Analysis of chimeric status was performed in 11 patients 2 to 8 years after BMT (Table 3) . In all patients, the T cells In the group of split chimeras, 5 of 9 did not receive conditioning for their last BMT, 2 of 9 received only cyclophosphamide, and 2 of 9 patients received cyclophosphamide and TBI. Fourteen patients (58%) are alive 7 months to 9.8 years (median, 44 months) after BMT (Fig I) . One of these patients (UPN 57) has recently developed anemia and thrombocytopenia 6 weeks after a varicella infection in which she had an unremarkable course and a normal antibody response. Engraftment and function of her paternal T cells remain normal. Five patients died despite engraftment, 3 patients died of infections too early to evaluate engraftment, and 2 (both ADA-deficient) died without engrafting. One patient (UPN 9) died 5 years posttransplant of sepsis. He had developed symptoms consistent with maternal-fetal GVHD in infancy, although maternal engraftment was never documented. He also had several episodes of bacterial sepsis, including klebsiella meningitis pretransplant, and was severely developmentally delayed. Patients who had transplants at age 5 6 months had relatively enhanced survival rates (77% v 42%), although not significantly so (P = .14). Patients who received conditioning had a survival rate of 6 1% compared with 57% for those who received no conditioning.
T Cell Subsets and Proliferation
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T-cell Immunity
T-cell Counts
The mean times post-BMT for the absolute lymphocyte count (ALC), absolute T cell count (ATC), CD4+ cell count (ACD4), and CD8+ cell count (ACD8) to become normal were 12, 10.4, 10.7, and 10.1 months, respectively, with the large majority of patients becoming normal within 18 months (Fig 2) . Only one patient (UPN9) had low cell counts in his last follow-up 3.5 years post-BMT; he suffered from chronic lung disease and developmental delay secondary to meningitis and pneumonia before BMT, and died 5 years after BMT.
The kinetics of reconstitution of normal proportions of Tcell subsets were evaluable in 8 patients, in whom measurement of these subsets was begun immediately after the BMT (Fig 2) . T-helper cells (CD4+, leu8-) reached normal values earlier (mean, 2 months) than the inducer subset, generally within the first 3 to 6 months from BMT. Percentages of Tinducer cells (CD4+, le&) took 12 to 15 months (mean, 22 months) to become normal and, in at least 1 patient, 94 months.
The most recent follow-up of all 14 patients (Table 4) shows that almost all (12 of 14) have achieved normal numbers of CD4-helper, CD4-inducer, and CD8-cytotoxic cells, with patients UPN9 and UPNl l being the two exceptions. NK cell counts were not observed sequentially, but in the most recent follow-up, 7 of 14 patients had normal percentages of natural killer (NK) cells.
T-Cell Function
In the majority of the patients, T-cell function became normal within 1 year post-BMT (Fig 2) , with the average times for lymphocyte proliferative responses to PWM, PHA, and alloantigen (MLR) being 6.3, 7.3, and 7.8 months, respectively. In most, the first in vitro function that appeared after BMT was proliferative responses to PWM and alloantigen (median for both was 3.0 months). The median time to an initial response to PHA was 4.0 months (range, 1 to 6 months). The median times for a normal response to PWM, PHA, and alloantigen were 4.0, 5.5, and 7.0 months, respectively. The kinetics of recovery of T-cell responses to candida antigen were less uniform: whereas 6 patients showed a relFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From atively early normal proliferative response (3 to 14 months post-BMT), 2 patients tested had subnormal responses until 42 and 80 months after their BMT. There was no significant difference in the kinetics of recovery of T-cell numbers, subsets, or function between patients who were conditioned and those who weren't.
The most recent follow-up of T-cell function (Table 4) shows that all of the patients have a normal proliferative response to alloantigen and PWM, and 13 of 14 are normal with respect to the response to PHA. Nine of 12 patients who were immunized with TT (1.5 to 7.5 years after BMT) had a normal proliferative response to tetanus antigen. Almost all (1 1 of 14) of the patients respond to at least one soluble antigen (tetanus or candida).
B-Cell Immunity
B-Cell Counts
Four patients (all males) had normal B-cell counts before BMT. In the remaining patients, the percentage of B cells (%B) and absolute B cell counts (ABC) reached normal levels an average of 3 to 12 months after BMT, often within the first 6 months (Fig 3) . In 1 patient, recovery was achieved 2.5 years post-BMT, and 1 patient (UPN47) still (>49 months) has very few B cells, which were first detected 3 years after BMT. In summary, the latest follow-up shows that 12 of 14 patients have normal ABC and/or %B ( Table  5) .
B-Cell Function
B-cell proliferation in response to SAC mitogen was abnormally low when tested soon after BMT in 5 patients, and became normal within 5 to 12 months in 4 of them (data not shown). Three additional patients were tested later after BMT and all have normal responses to SAC (Table 5 ). In summary, 7 of 8 patients tested have a normal response to SAC, the only exception being patient UPN47, who has very few B cells and has negative results in all other B-cell studies.
Serum IgM also reached normal values less than 1 year after BMT in most patients (Fig 3) . However, 4 patients still have subnormal levels. Normal serum IgA was achieved within 1 to 2 years after BMT in 7 patients. However, this was delayed to the fourth year in 1 patient (UPN9) and is still subnormal in the remaining 6 patients ( Table 5) .
SpeciJic antibody production. Normal isohemagglutinin titers (ISH) were achieved 9 to 32 months (mean, 22 months) after BMT in 9 of 13 patients tested sequentially (Fig 3) . Five of 10 patients tested produced normal or borderline levels of specific antibodies in response to immunization with PPS (Table 5) . Five of 10 patients began producing specific anti-PPS antibodies 9 months to 6.5 years after BMT, and 1 patient (UPN5 1) produced borderline/low levels of antibodies 6 months post-BMT (data not shown). Specific antibody production in response to KLH was found in 3 of 10 patients tested ( Table 5 ). Ten patients were immunized with a series ofthree TT vaccines; ofthese, 4 responded with normal titers of anti-TT-specific antibodies. Eight of the 14 patients observed for more than 12 months were able to be taken off
Mitogen stimulation.
Ig production. gammaglobulin therapy. Production of normal titers of ISH tended to be predictive of normal anti-PPS antibody production (P < .064), and normal pre-BMT B-cell counts did not predict future normal specific antibody production (P = .17).
DISCUSSION
Haplocompatible T-cell-depleted BMT can be a successful, curative treatment for patients with SCID who lack HLAmatched related donors. The number of patients in our series and the long follow-up (>9 years) enabled us to delineate the course and extent of immune reconstitution after transplantation, as well as provide an overview of the clinical outcome: survival, engraftment, and long-term health status.
The survival rate in our group of patients is 14 of 24 (58%), which is comparable to that found in other large series,6,8-"~24,25 with age less than 6 months being a favorable risk factor, as also reported by other^.'^,^^ Twelve of the 14 patients are clinically healthy, free of infections, and 7 of 14 are receiving no treatment other than parenteral gammaglobulin. Our marrow processing method, first described by Reisner et al,26327 depletes greater than 99% of mature T cells, significantly reduces the incidence and severity of GVHD, and eliminates the need for prophylactic immunosuppressive treatment; none of our patients had acute or chronic GVHD greater than grade I. We have also had no cases of B-cell lymphoproliferative disorders, which have been described after MoAb T-cell-depleted BMT."
Three of the 10 patients who died after a T-cell-depleted BMT had ADA-deficient SCID. The first patient (UPN8) received no conditioning and failed to engraft. The parents refused a second transplant with conditioning therapy, and the child ultimately died of disseminated atypical mycobacterium infection. The second child (UPN12) had chronic lung disease at diagnosis and was treated with experimental conditioning regimens (deoxyadenosine and anti-leu 1 MoAb), but failed to engraft." The third child (UPN 17) did not engraft after the first transplant without conditioning and died of parainfluenza viral pneumonia within 2 weeks of conditioning for her second transplant. Alternative therapies, including polyethylene glycol (PEG)-ADA and gene transfer, can now be considered for some of these patients with ADA deficiency who lack HLA-matched donors, although the only curative treatment remains a BMT.
Durable T-cell engraftment was achieved in 19 of 2 I evaluable patients, with 6 of 19 requiring more than one transplant to achieve engraftment. Sex of the donor and recipient, patient's age, cell dose, and type of SCID (with or without B cells) had no observable effect on T-cell engraftment in our series. Donor B-cell and monocyte engraftment were achieved in 2 of 11 patients tested. This appears to be linked to aggressive conditioning (Cy/TBI), as observed by o t h e r~,~~l~~~~ although the number of patients is small.
Recovery of T-cell immunity after transplant begins relatively early and is extensive. T-cell function appeared on average 3.5 to 4.7 months post-BMT, with half the patients showing a response to mitogen or alloantigen by 3.0 months. The average time to normal T-cell and major subset numbers was 11 and 9 months, respectively, and to normal function 6 to 8 months. Virtually all patients had normal cell counts and phenotypes and had normal responses to mitogens and alloantigens and most responded to candida antigen 12 to 18 months after transplant. Only the CD4-inducer subset appears to be delayed, with some patients requiring many years to become normal. We could find no effect of conditioning on the kinetics of recovery, although the number of evaluable patients is small. In general, our results are comparable to those reported by other groups,'.' although it is difficult to make direct comparisons. For example, in one report' all of the SCID in whom kinetics were reported were SCID with B cells, a much more uniform population than ours. However, in this group, T-cell function was detected approximately 1 to 9 months post-T-celldepleted transplant, with normal function appearing 3 to 7 months post-BMT. In another report'' of 8 evaluable patients with SCID, T-cell numbers and function recovered between 1 to 7 months posttransplant. Finally, in a retrospective report' I comparing recipients of HLA-matched marrow to those of T-cell-depleted, mismatched marrow, the former group appeared to recover T-and B-cell function significantly earlier (6 months) than the latter group (1 6 months). Interestingly, patients in this group who were treated with conditioning therapy before transplant were more likely to recover specific antibody production. In our group, we could find no difference (2 of 4 without v 6 of 10 with conditioning), although the numbers are small.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From B-cell recovery is delayed relative to T-cell immune reconstitution and can take many years. Some parameters of humoral immunity are normal within 12 to 15 months after BMT, including number and percent B cells, surface Igs and serum levels of IgM, but these may sometimes be delayed until the third and fourth year after transplantation. In contrast, B-cell function, as evidenced by antibodies to blood types or specific antibody production in response to immunization by PPS, KLH, or TT, has appeared in 10 of the 14 patients, sometimes up to 8 years after BMT. It is important to emphasize that B-cell function can recover after this type of transplant, but that it may take many years.
Several groups have reported that B-cell reconstitution may depend on the origin of the B cells (host v donor or mixed origin) and is enhanced in complete hime eras.^,*^^,'',*^,^^ In the 11 patients in whom we evaluated the origin of B cells and monocytes, we found no effect of chimeric state on functional B-cell recovery; in both complete and mixed chimeras, approximately half have good recovery, although only 2 of I 1 patients studied were complete chimeras. This is in agreement with the observation that the immune defect in at least some SCID patients may be restricted to T cells, whereas their B cells (if present) are often inherently normal (although possibly arrested at an early developmental stage) and function well in the presence of normal HLA-compatible or haplocompatible T cells.3s32 However, in several studies of X chromosome inactivation patterns in X-linked SCID, B cells in obligate camers demonstrate preferential use of the nonmutant X as the active X, suggesting defective B cells in these patient^.^' However, other studies have also shown preferential use of the normal X in fibroblasts, monocytes, and granulocytes, the interpretation of which remains controversia1.34,35 It is unclear from our results why there is a delay in recovery of normal B-cell immunity in this patient population in which many T-cell numbers and functions have returned to normal. It is certainly possible that there exist T-cell (or B-cell) subsets that we have not measured that are slow to return to normal post-BMT.
The strongest predictor of recovery of B-cell function in our study was the production of ISH (P < .064). Even patient UPN47, who completely lacked B cells for 3 years after BMT, is beginning to show initial signs of B-cell recovery, with an increase in B-cell percentage and absolute B-cell counts. This significant delay in B-cell reconstitution has also been reported by others,"" and therefore we remain optimistic regarding future prospects for complete immune reconstitution in many of these patients.
